Effectiveness of a Novel Workplace-based Exercise Intervention: a Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Change in maximal aerobic capacity
研究概览
简要总结
Sufficient physical activity and a good cardiorespiratory fitness level (CRF) are central in cardiovascular disease (CVD) risk reduction. However, many people remain inactive, partly because current exercise recommendations fail to address important barriers to exercise. A novel exercise protocol has previously been developed called 'reduced-exertion high-intensity interval training' (REHIT), which can remove several common perceived barriers to exercise. REHIT 1) improves CRF and other key CVD risk factors, 2) is genuinely time-efficient (total time-commitment of just 2x10 min per week), 3) is well-tolerated, manageable, and not associated with negative affective responses, and 4) can be done in the workplace, in work-clothes and without a need to shower afterwards. To date, this intervention has only been investigated in a lab-setting. Therefore, in the present randomised controlled trial, the 'real-world' effectiveness of REHIT in improving maximal aerobic capacity (V̇O2max; a key risk factors of CVD) will be investigated in a workplace setting. Participants' attitudes and psychological responses to REHIT will be assessed to evaluate the likelihood of successful implementation. In 2 study centres, a total of up to n=50 physically inactive male and female office workers will be recruited to perform 6 weeks of unsupervised, computer-guided, office-based REHIT (n=25) or act as a control (n=25).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Employee at participating workplace
排除标准
- •Aged < 18 years or > 60 years
- •History of type 2 diabetes
- •Insulin therapy
- •Use of β-blockers
- •Use of inhaled steroids (e.g. for asthma)
- •Any cardiovascular condition with the exception of well-controlled uncomplicated hypertension (systolic >140 mm Hg and/or >90 mm Hg after at least 5 minutes of seated rest), which is treated with no more than two drugs (either an ACE, ARB, calcium channel blocker, or diuretic)
- •Cerebrovascular disease including previous stroke or aneurysm
- •History of exercise-induced asthma
- •History of type 1 diabetes mellitus or a history of ketoacidosis
- •History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug or chemical-induced, and post organ transplant)
- •History of respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease
- •History of musculoskeletal or neurological disorders
- •Active inflammatory bowel disease
- •History of renal disease
- •Other metabolic diseases, including hyper/ hypo-parathyroidism, hyper/hypo-thyroidism, and Cushing's disease.
- •BMI>35 kg/m2
- •A clinically significant resting ECG abnormality at the pre-screening visit which in the opinion of the cardiologist exposes the participant to risk by take part in the main trial.
- •'Yes' to any questions on a standard physical activity readiness questionnaire (PARQ)
- •Classification as moderately or highly physically active on the International Physical Activity Questionnaire (IPAQ)
- •Current participation in another research study
- •Inability to fully understand the verbal and written descriptions of the study in English, and the instructions provided during the study
研究组 & 干预措施
Exercise
Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
干预措施: Reduced-Exertion High-Intensity Interval Training (REHIT) (Behavioral)
Control
The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
结局指标
主要结局
Change in maximal aerobic capacity
时间窗: Change from baseline to 3 days after the 6-week intervention
Aerobic capacity: a key risk factor of noncommunicable disease
次要结局
- Change in motivation for exercise(Change from baseline to 3 days after the 6-week intervention)
- Change in perceived stress(Change from baseline to 3 days after the 6-week intervention)
- Intervention acceptability(3 days after the 6-week intervention)
- Change in health status(Change from baseline to 3 days after the 6-week intervention)
研究者
Niels Vollaard
Principal Investigator
University of Stirling